{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:36:00Z","timestamp":1785818160813,"version":"3.56.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Keryx Biopharmaceuticals, Inc."}],"content-domain":{"domain":["jrnjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Renal Nutrition"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1053\/j.jrn.2016.01.009","type":"journal-article","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T20:54:26Z","timestamp":1456347266000},"page":"209-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["An Update on Phosphate Binders: A Dietitian's Perspective"],"prefix":"10.1053","volume":"26","author":[{"given":"Lisa","family":"Gutekunst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.jrn.2016.01.009_bib1","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2016.01.009_bib2","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1046\/j.1523-1755.62.s82.15.x","article-title":"Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon","volume":"62","author":"Qunibi","year":"2002","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.jrn.2016.01.009_bib3","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.ASN.0000113243.24155.2F","article-title":"Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes","volume":"15","author":"Stevens","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2016.01.009_bib4","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"},{"key":"10.1053\/j.jrn.2016.01.009_bib5","doi-asserted-by":"crossref","first-page":"5P","DOI":"10.1042\/cs041005Pa","article-title":"The effect of aluminium hydroxide on calcium, phosphorus and aluminium balances and the plasma parathyroid hormone in patients with chronic renal failure","volume":"41","author":"Bailey","year":"1971","journal-title":"Clin Sci"},{"key":"10.1053\/j.jrn.2016.01.009_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2016.01.009_bib7","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2016.01.009_bib8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients","volume":"71","author":"Block","year":"2007","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2016.01.009_bib9","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1093\/ndt\/gfm424","article-title":"Factors associated with mortality in patients new to haemodialysis","volume":"22","author":"Spiegel","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.jrn.2016.01.009_bib10","doi-asserted-by":"crossref","first-page":"c259","DOI":"10.1159\/000313484","article-title":"Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients","volume":"115","author":"Zhang","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"10.1053\/j.jrn.2016.01.009_bib11","unstructured":"Genzyme Corporation. About Genzyme. Cambridge, MA. Available at: http:\/\/www.genzyme.com\/Company\/About-Genzyme.aspx Accessed April 1,\u00a02015."},{"key":"10.1053\/j.jrn.2016.01.009_bib12","unstructured":"Drugs@FDA Approved Drug Products Database. Available at: http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm Accessed April 1,\u00a02015."},{"key":"10.1053\/j.jrn.2016.01.009_bib13","series-title":"Fosrenol [Prescribing Information]","year":"2014"},{"key":"10.1053\/j.jrn.2016.01.009_bib14","series-title":"Phoslyra [Prescribing Information]","year":"2011"},{"key":"10.1053\/j.jrn.2016.01.009_bib15","series-title":"Renvela [Prescribing Information]","year":"2009"},{"key":"10.1053\/j.jrn.2016.01.009_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/1744-9987.12068","article-title":"Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia","volume":"18","author":"Akizawa","year":"2014","journal-title":"Ther Apher Dial"},{"key":"10.1053\/j.jrn.2016.01.009_bib17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1471-2369-15-98","article-title":"Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial","volume":"15","author":"Akizawa","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.jrn.2016.01.009_bib18","series-title":"Velphoro [Prescribing Information]","year":"2013"},{"key":"10.1053\/j.jrn.2016.01.009_bib19","series-title":"Auryxia [Prescribing Information]","year":"2014"},{"key":"10.1053\/j.jrn.2016.01.009_bib20","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients","volume":"3","author":"Cheng","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2016.01.009_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000351850","article-title":"Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease","volume":"123","author":"Block","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"10.1053\/j.jrn.2016.01.009_bib22","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2016.01.009_bib23","unstructured":"Renagel [Prescribing Information]. 2014. Cambridge, MA 02142: Genzyme Inc."},{"key":"10.1053\/j.jrn.2016.01.009_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1525-139X.2011.00849.x","article-title":"The phosphate binder equivalent dose","volume":"24","author":"Daugirdas","year":"2011","journal-title":"Semin Dial"},{"key":"10.1053\/j.jrn.2016.01.009_bib25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1681\/ASN.2011070688","article-title":"Effects of frequent hemodialysis on measures of CKD mineral and bone disorder","volume":"23","author":"Daugirdas","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2016.01.009_bib26","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"79","year":"2009","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2016.01.009_bib27","doi-asserted-by":"crossref","first-page":"456","DOI":"10.5301\/jn.5000189","article-title":"An update on calcium metabolism alterations and cardiovascular risk in patients with chronic kidney disease: questions, myths and facts","volume":"26","author":"Savica","year":"2013","journal-title":"J Nephrol"},{"key":"10.1053\/j.jrn.2016.01.009_bib28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/ncpneph0710","article-title":"Should we be using calcium-containing phosphate binders in patients on dialysis?","volume":"4","author":"Spiegel","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1053\/j.jrn.2016.01.009_bib29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1525-139X.1998.tb00363.x","article-title":"Current and future therapies for the medical management of secondary hyperparathyroidism","volume":"11","author":"Chertow","year":"1998","journal-title":"Semin Dial"},{"key":"10.1053\/j.jrn.2016.01.009_bib30","series-title":"Wolters Kluwer Health. Philadelphia, PA Handbook of dialysis","article-title":"Bone disease","author":"Daugirdas","year":"2015"},{"key":"10.1053\/j.jrn.2016.01.009_bib31","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/ndt\/9.8.1121","article-title":"Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis","volume":"9","author":"Pflanz","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.jrn.2016.01.009_bib32","first-page":"23","article-title":"Effectiveness of calcium acetate as a phosphate binder in patients undergoing continuous ambulatory peritoneal dialysis","volume":"4","author":"Choy","year":"1998","journal-title":"Hong Kong Med J"},{"key":"10.1053\/j.jrn.2016.01.009_bib33","first-page":"26","article-title":"Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis","volume":"19","author":"Saif","year":"2007","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"10.1053\/j.jrn.2016.01.009_bib34","series-title":"Phoslo [Prescribing Information]","year":"2014"},{"key":"10.1053\/j.jrn.2016.01.009_bib35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1523-1755.1999.00240.x","article-title":"RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder lowers serum phosphorus and serum parathyroid hormone. The RenaGel Study Group","volume":"55","author":"Slatopolsky","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2016.01.009_bib36","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0272-6386(99)70221-0","article-title":"A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients","volume":"33","author":"Bleyer","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2016.01.009_bib37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/1471-2369-14-226","article-title":"Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review","volume":"14","author":"Zhang","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.jrn.2016.01.009_bib38","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/ndt\/gfh282","article-title":"Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate","volume":"19","author":"Hutchison","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.jrn.2016.01.009_bib39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5414\/CNP62193","article-title":"Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis","volume":"62","author":"Finn","year":"2004","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.jrn.2016.01.009_bib40","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1185\/030079907X242719","article-title":"A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate","volume":"23","author":"Sprague","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1053\/j.jrn.2016.01.009_bib41","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/PAS.0000000000000385","article-title":"Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate","volume":"39","author":"Haratake","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.jrn.2016.01.009_bib42","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1046\/j.1523-1755.63.s85.18.x","article-title":"A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients","volume":"63","author":"D'Haese","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.jrn.2016.01.009_bib43","first-page":"284","article-title":"Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years","volume":"70","author":"Malluche","year":"2008","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.jrn.2016.01.009_bib44","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","article-title":"Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up","volume":"21","author":"Spasovski","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.jrn.2016.01.009_bib45","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1053\/j.ajkd.2010.11.028","article-title":"Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study","volume":"57","author":"Martin","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2016.01.009_bib46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5414\/CN108119","article-title":"The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in\u00a0vitro","volume":"81","author":"Wilhelm","year":"2014","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.jrn.2016.01.009_bib47","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2215\/CJN.08230811","article-title":"Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients","volume":"8","author":"Wuthrich","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2016.01.009_bib48","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2016.01.009_bib49","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Long-term effects of iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","volume":"30","author":"Floege","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.jrn.2016.01.009_bib50","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1053\/j.ajkd.2012.11.041","article-title":"Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial","volume":"61","author":"Dwyer","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2016.01.009_bib51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/j.ajkd.2015.03.013","article-title":"The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial","volume":"66","author":"Van Buren","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2016.01.009_bib52","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in dialysis patients","volume":"26","author":"Lewis","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2016.01.009_bib53","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000348805","article-title":"Ferric citrate hydrate, a\u00a0new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification","volume":"37","author":"Lida","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.jrn.2016.01.009_bib54","doi-asserted-by":"crossref","first-page":"F1466","DOI":"10.1152\/ajprenal.00279.2009","article-title":"Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate","volume":"297","author":"Giral","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1053\/j.jrn.2016.01.009_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.jrn.2010.11.007","article-title":"Salivary glands: a new player in phosphorus metabolism","volume":"21","author":"Savica","year":"2011","journal-title":"J Ren Nutr"},{"key":"10.1053\/j.jrn.2016.01.009_bib56","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1681\/ASN.2008020130","article-title":"Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients","volume":"20","author":"Savica","year":"2009","journal-title":"J Am Soc Nephrol"}],"container-title":["Journal of Renal Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051227616000108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051227616000108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T22:55:59Z","timestamp":1536965759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051227616000108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1051227616000108"],"URL":"https:\/\/doi.org\/10.1053\/j.jrn.2016.01.009","relation":{},"ISSN":["1051-2276"],"issn-type":[{"value":"1051-2276","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Update on Phosphate Binders: A Dietitian's Perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Renal Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jrn.2016.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}